Key Takeaways
- Revenue up 28% YoY, but margin pain acute: Volume grew 6% and realizations improved, yet EBITDA margin stood at 18% as a spike in coal and energy costs could not be fully passed through in the quarter.
- The chlorine floor is the structural story: Management declared they believe chlorine prices will not return to negative territory going forward, a permanent shift in the chlor-alkali industry’s pricing power that changes the earnings profile of the entire chain.
- Capex cycle is about to convert: CPVC and Epichlorohydrin plants enter commissioning within a quarter, while the epoxy resin and multi-purpose plant projects are moving from board approval to pilot-plant stage.
- FY31 revenue path laid out with asset-turnover math: Management walked investors from the current ~₹3,000 Cr gross block to ~₹4,200 Cr, implying a ~₹5,000–5,100 Cr revenue target at optimum utilization, without relying on price assumptions.
- What to watch next quarter: Whether CPVC and ECH plants commission on time, the trajectory of caustic soda prices through the European winter, and any stabilization in the coal cost base that has squeezed chlor-alkali margins.
Chlor-Alkali: The Margin Squeeze and the Chlorine Floor
- Coal cost shock: Coal prices rose 60–70% over the last 3–4 months, directly inflating energy costs for the chlor-alkali chain and driving the ₹43 Cr sequential drop in operating profit.
- Caustic soda lagged the energy move: Global caustic soda prices did not rise enough to absorb the higher energy cost, so the entire burden shifted onto the chlorine side, where domestic pricing allows faster pass-through.
- Chlorine demand is absorbing the pass-through: Demand for chlorine derivatives has increased over the last 6 months and is expected to strengthen further over the next 6 months, giving management confidence that the price increases will stick.
- The new norm: Management stated chlorine prices will not go into negative zone going forward, a structural change in the domestic chlor-alkali industry because chlorine is not globally priced and domestic demand is firm.
Maulik Patel: "I think going forward, we will not see the chlorine prices in the negative zone going forward from here onwards. And that is much easier to increase the price pass on because caustic is globally decided in terms of the pricing, but the chlorine is domestic-based only."
Capex Pipeline: Commissioning, Pilots, and the FY31 Math
- CPVC and Epichlorohydrin near the finish line: Both capacity expansions are in final stages with trial runs underway and are expected to commission within a quarter, adding ~₹500–600 Cr to the gross block.
- Epoxy resin and multi-purpose plant progressing: Pilot plants are now ready and the customer approval process will begin soon, keeping the projects on track following last quarter’s Board approval.
- Hydrogen peroxide for solar application: A value-added hydrogen peroxide plant targeting the solar niche will commission in Q4 FY27; volumes are not substantial relative to total plant size but the application carries a specialty margin.
- Chlorotoluene ramp-up: Volume is increasing quarter-on-quarter and revenue is expected to reach close to ₹100 Cr this year; peak revenue at optimum utilization is around ₹300 Cr, with further upside from value-added chemistry now in pilot.
- FY31 revenue bridge via gross block: Current gross block of ~₹3,000 Cr rises to ~₹3,500 Cr once CPVC and ECH commission, then to ~₹4,100–4,200 Cr after epoxy and MPP capex of ~₹600 Cr; at current realizations and gradual ramp-up, that asset base can deliver ~₹5,000–5,100 Cr revenue by FY31.
- ECH ramp and captive use: Once the plant doubles, ramp-up will be gradual; management estimates roughly 50% of ECH will be consumed captively for epoxy resin, with the balance sold in the merchant market, and epoxy commissioning is targeted for March 2028, driving revenue from FY29 onward.
CPVC: Demand, Supply, and the Moat
- Demand growing at 13% CAGR: Management expects India’s demand growth will be sufficient to absorb all new supplies over a 3–4 year horizon, though any single year can see lumpiness because supply arrives in large blocks while demand grows gradually.
- First-mover advantages are durable: CPVC technology is not easily available, the customer approval process takes time, and Epigral’s in-house chlorine delivered via pipeline adds a structural cost and integration benefit that new entrants cannot quickly replicate.
Milind Kotecha: " So it's not that easily available. Plus, also, it takes time to get approval, then you get the volumes from the customers. So it's a gradual process. So it's not that easy. So first-mover advantages will always be there."
Specialty Transition and the Chlorotoluene Bet
- Derivatives and specialty share at 57%: Revenue contribution from derivatives and specialty business reached 57% in Q2 FY27, and management expects this transition to accelerate as capex projects come online.
- Chlorotoluene focus is on molecules nobody else makes in India: The company is concentrating on ortho-chlorotoluene and para-chlorotoluene, moving into value-added chemistry for pharma intermediates and agro intermediates, and explicitly staying away from the benzyl alcohol / benzyl chloride value chain.
- Value-added approvals expected faster: Customer approvals for the chlorotoluene value-added chemistry are expected to take place much faster than in the past, supported by the pilot plant commissioned last quarter.
Maulik Patel: " Our focus is the ortho-chlorotoluene and para-chlorotoluene, which is nobody is manufacturing in India. And we are going forward in terms of the value-added chemistry for the pharma intermediate and the agro intermediate, which can consume this chemistry right now."
Energy Strategy: Renewables Without Heavy Capex
- 30–35% renewable power in 2–3 years: The company targets meeting 30% to 35% of total power demand from solar and wind hybrid projects over the next 2–3 years, with the first hybrid project already commissioned and a second already announced.
- Capital-light structure: Epigral is not investing substantially; it holds only 26% equity in the SPV with a long-term 20-year commitment, so the renewable build-out does not represent a major capex call on the balance sheet.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CPVC and ECH plant commissioning | Both plants to commission after trial runs currently underway | Within a quarter |
| Hydrogen peroxide (solar grade) commissioning | Value-added plant for solar application to commission | Q4 FY27 |
| Epoxy resin plant commissioning | Plant to be commissioned and drive revenue | March 2028, revenue FY29 onward |
| FY31 revenue target | ~₹5,000–5,100 Cr at optimum utilization, based on current realizations and gradual ramp-up | FY31 |
| Renewable power share | 30% to35% of total power demand from solar and wind hybrid | 2–3 years |
| Chlorine price floor | Chlorine prices will not go into negative zone going forward | Ongoing, from current quarter |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹752 cr, +28% YoY from ₹589 cr in Q2 FY26 |
| Sales volume growth | 6% YoY |
| EBITDA | ₹136 cr, +3% YoY from ₹132 cr in Q2 FY26 |
| EBITDA margin | 18%, impacted by high raw material costs from global uncertainty |
| PAT | ₹64 cr, +26% YoY from ₹51 cr in Q2 FY26 |
| H1 FY27 revenue | ₹1,461 cr, +21% YoY from ₹1,204 cr in H1 FY26 |
| H1 FY27 EBITDA margin | 22% |
| H1 FY27 PAT | ₹164 cr, vs ₹131 cr in H1 FY26 |
| H1 FY27 PAT margin | 11%, similar to H1 FY26 |
| ROCE | 15% as on 30 Sep 2026; 18% excluding capital work in progress |
| Net debt to EBITDA | 0.9x as on 30 Sep 2026, vs 0.8x as on 30 Sep 2025 |
| Net debt | ₹514 cr as on 30 Sep 2026, vs ₹496 cr as on 30 Sep 2025 |
| Capex spent in H1 FY27 | ₹88 cr |
| Derivatives and specialty revenue share | 57% of total revenue in Q2 FY27 |
| ECU realization | ₹31,000–₹32,000 in Q2 FY27; currently ₹32,000–₹33,000 |
| Chlorine price | ~₹0 in Q2 FY27 and currently |
| CPVC realization | ₹120–₹125 per kg |
| CPVC capacity utilization | 60–65% |
| ECH capacity utilization | 75–80% |
| Hydrogen peroxide capacity utilization | 95% |
| Caustic soda capacity utilization | 75% |
| Chlorotoluene expected FY27 revenue | ~₹100 cr |
| Chlorotoluene peak revenue potential | ₹300–₹350 cr at optimum utilization |
| CPVC demand growth | 13% CAGR annually |
| Gross block | ~₹3,000 cr currently; expected to reach ₹3,500 cr post CPVC and ECH expansion commissioning |
| FY31 revenue target | ₹5,000–₹5,100 cr, based on current realizations and gradual ramp-up of capex |
| ECH captive consumption estimate | ~50% captively consumed once epoxy resin plant commissions, balance 50% sold in market |